Increasing plasma fibrinogen, but unchanged levels of intraplatelet cyclic nucleotides, plasma endothelin-1, factor VII, and neopterin during cholesterol lowering with fluvastatin.
Lipid-lowering statin treatment reduces cardiovascular morbidity and mortality and improves endothelial function in patients with hypercholesterolemia. The aim of the present study was to evaluate plasma levels of fibrinogen, factor VII, and the macrophage-derived inflammatory mediator neopterin during lipid lowering. In addition, the endothelial production of platelet antiaggregatory and vasodilatory factors such as nitric oxide and prostacyclin, and vasoconstrictive factors such as endothelin-1, was assessed. Plasma fibrinogen, factor VII, endothelin-1, and the neopterin and intraplatelet nitric oxide and prostacyclin mediators cyclic 3'-5'guanosine monophosphate (cGMP) and cyclic 3'-5'adenosine monophosphate (cAMP) were measured before and 6 months after the institution of treatment with fluvastatin in 17 patients (eight men and nine women, median age 60 years) with vascular disease and previously untreated hypercholesterolemia. After 6 months, a decrease of 1.62 mmol/l [1.26-2.18 (19%); P < 0.01] was noted in levels of total cholesterol, and a decrease of 1.70 mmol/l [1.52-2.30 (28%); P < 0.01] in levels of low-density lipoprotein cholesterol. Plasma levels of fibrinogen had increased [from 4.81 g/l (4.26-5.27) to 5.17 g/l (4.81-5.67); P < 0.05], whereas no significant changes had occurred in intraplatelet levels of cGMP [decrease by 0.05 pmol/10(9) platelets (-0.17 to 0.24); NS], cAMP [decrease by 0.13 pmol/10(9) platelets (-0.37 to 0.86); NS], plasma endothelin-1 [decrease by 0.05 pg/ml (-0.60 to 0.70); NS], plasma factor VII [from 1.14 IE/ml (0.58-1.38) to 1.22 IE/ml (0.96-1.46); NS], or plasma neopterin [from 8.6 nmol/l (7.1-11.5) to 8.7 nmol/l (7.9-11.3); NS]. In conclusion, during cholesterol-lowering treatment with fluvastatin, plasma levels of fibrinogen increased whereas intraplatelet cyclic nucleotide levels and plasma endothelin-1, factor VII and neopterin levels were unchanged.
Gottsäter
A
A
Department of Vascular and Renal Diseases, University of Lund, University Hospital MAS, Malmö, Sweden. Anders.Gottsater@medforsk.mas.lu.se
Anwaar
I
I
Lind
P
P
Mattiasson
I
I
Lindgärde
F
F
D000368:Aged; D000924:Anticholesteremic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001792:Blood Platelets / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000150:complications; D002784:Cholesterol / Q000097:blood; D019332:Endothelin-1 / Q000097:blood*; D005167:Factor VII / Q000378:metabolism*; D005229:Fatty Acids, Monounsaturated / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005340:Fibrinogen / Q000378:metabolism*; D000077340:Fluvastatin; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood* / Q000188:drug therapy* / Q000209:etiology; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D019798:Neopterin / Q000097:blood*; D009712:Nucleotides, Cyclic / Q000378:metabolism*
D000924:Anticholesteremic Agents; D019332:Endothelin-1; D005229:Fatty Acids, Monounsaturated; D007211:Indoles; D009712:Nucleotides, Cyclic; D000077340:Fluvastatin; D019798:Neopterin; D005167:Factor VII; D005340:Fibrinogen; D002784:Cholesterol